Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Vaccines

  Free Subscription


Articles published in Virology

Retrieve available abstracts of 36 articles:
HTML format
Text format



Single Articles


    July 2017
  1. BONJARDIM CA
    Viral exploitation of the MEK/ERK pathway - A tale of vaccinia virus and other viruses.
    Virology. 2017;507:267-275.
    PubMed     Text format     Abstract available


    June 2017
  2. FREY TR, Lehmann MH, Ryan CM, Pizzorno MC, et al
    Ectromelia virus accumulates less double-stranded RNA compared to vaccinia virus in BS-C-1 cells.
    Virology. 2017;509:98-111.
    PubMed     Text format     Abstract available


  3. DENG L, Kim JR, Chang TZ, Zhang H, et al
    Protein nanoparticle vaccine based on flagellin carrier fused to influenza conserved epitopes confers full protection against influenza A virus challenge.
    Virology. 2017;509:82-89.
    PubMed     Text format     Abstract available


  4. RUSSELL CJ, Jones BG, Sealy RE, Surman SL, et al
    A Sendai virus recombinant vaccine expressing a gene for truncated human metapneumovirus (hMPV) fusion protein protects cotton rats from hMPV challenge.
    Virology. 2017;509:60-66.
    PubMed     Text format     Abstract available


    May 2017
  5. SUN X, Belser JA, Pulit-Penaloza JA, Creager HM, et al
    Stockpiled pre-pandemic H5N1 influenza virus vaccines with AS03 adjuvant provide cross-protection from H5N2 clade 2.3.4.4 virus challenge in ferrets.
    Virology. 2017;508:164-169.
    PubMed     Text format     Abstract available


    April 2017
  6. MEADOR LR, Kessans SA, Kilbourne J, Kibler KV, et al
    A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles.
    Virology. 2017;507:242-256.
    PubMed     Text format     Abstract available


  7. YEE PT, Laa Poh C
    Impact of genetic changes, pathogenicity and antigenicity on Enterovirus- A71 vaccine development.
    Virology. 2017;506:121-129.
    PubMed     Text format     Abstract available


    February 2017
  8. BANERJEE S, Shi H, Banasik M, Moon H, et al
    Evaluation of a novel multi-immunogen vaccine strategy for targeting 4E10/10E8 neutralizing epitopes on HIV-1 gp41 membrane proximal external region.
    Virology. 2017;505:113-126.
    PubMed     Text format     Abstract available


  9. RODRIGUEZ L, Nogales A, Reilly EC, Topham DJ, et al
    A live-attenuated influenza vaccine for H3N2 canine influenza virus.
    Virology. 2017;504:96-106.
    PubMed     Text format     Abstract available


    January 2017
  10. LEE YH, Jang YH, Seong BL
    Cell-cultured, live attenuated, X-31ca-based H5N1 pre-pandemic influenza vaccine.
    Virology. 2017;504:73-78.
    PubMed     Text format     Abstract available


  11. PEETERS B, Reemers S, Dortmans J, de Vries E, et al
    Genetic versus antigenic differences among highly pathogenic H5N1 avian influenza A viruses: Consequences for vaccine strain selection.
    Virology. 2017;503:83-93.
    PubMed     Text format     Abstract available


  12. KIM SH, Paldurai A, Samal SK
    A novel chimeric Newcastle disease virus vectored vaccine against highly pathogenic avian influenza virus.
    Virology. 2017;503:31-36.
    PubMed     Text format     Abstract available


  13. GALLAGHER JR, Torian U, McCraw DM, Harris AK, et al
    Characterization of the disassembly and reassembly of the HBV glycoprotein surface antigen, a pliable nanoparticle vaccine platform.
    Virology. 2017;502:176-187.
    PubMed     Text format     Abstract available


  14. WANG J, Zhang Y, Zhang X, Hu Y, et al
    Pathologic and immunologic characteristics of coxsackievirus A16 infection in rhesus macaques.
    Virology. 2017;500:198-208.
    PubMed     Text format     Abstract available


    December 2016
  15. FERNANDEZ-SAINZ I, Medina GN, Ramirez-Medina E, Koster MJ, et al
    Adenovirus-vectored foot-and-mouth disease vaccine confers early and full protection against FMDV O1 Manisa in swine.
    Virology. 2016;502:123-132.
    PubMed     Text format     Abstract available


  16. PUSHKO P, Tretyakova I, Hidajat R, Zsak A, et al
    Virus-like particles displaying H5, H7, H9 hemagglutinins and N1 neuraminidase elicit protective immunity to heterologous avian influenza viruses in chickens.
    Virology. 2016;501:176-182.
    PubMed     Text format     Abstract available


    November 2016
  17. CHENG BY, Nogales A, de la Torre JC, Martinez-Sobrido L, et al
    Development of live-attenuated arenavirus vaccines based on codon deoptimization of the viral glycoprotein.
    Virology. 2016;501:35-46.
    PubMed     Text format     Abstract available


  18. ISAKOVA-SIVAK I, Korenkov D, Smolonogina T, Tretiak T, et al
    Comparative studies of infectivity, immunogenicity and cross-protective efficacy of live attenuated influenza vaccines containing nucleoprotein from cold-adapted or wild-type influenza virus in a mouse model.
    Virology. 2016;500:209-217.
    PubMed     Text format     Abstract available


  19. MATZINGER SR, Opriessnig T, Xiao CT, Catanzaro N, et al
    A chimeric virus created by DNA shuffling of the capsid genes of different subtypes of porcine circovirus type 2 (PCV2) in the backbone of the non-pathogenic PCV1 induces protective immunity against the predominant PCV2b and the emerging PCV2d in pigs
    Virology. 2016;498:82-93.
    PubMed     Text format     Abstract available


    October 2016
  20. YAMSHCHIKOV V, Manuvakhova M, Rodriguez E, Hebert C, et al
    Development of a human live attenuated West Nile infectious DNA vaccine: Identification of a minimal mutation set conferring the attenuation level acceptable for a human vaccine.
    Virology. 2016;500:122-129.
    PubMed     Text format     Abstract available


  21. NOGALES A, Huang K, Chauche C, DeDiego ML, et al
    Canine influenza viruses with modified NS1 proteins for the development of live-attenuated vaccines.
    Virology. 2016;500:1-10.
    PubMed     Text format     Abstract available


  22. LULF AT, Freudenstein A, Marr L, Sutter G, et al
    Non-plaque-forming virions of Modified Vaccinia virus Ankara express viral genes.
    Virology. 2016;499:322-330.
    PubMed     Text format     Abstract available


  23. GARG R, Theaker M, Martinez EC, van Drunen Littel-van den Hurk S, et al
    A single intranasal immunization with a subunit vaccine formulation induces higher mucosal IgA production than live respiratory syncytial virus.
    Virology. 2016;499:288-297.
    PubMed     Text format     Abstract available


    September 2016
  24. RAUFF D, Strydom C, Abolnik C
    Evolutionary consequences of a decade of vaccination against subtype H6N2 influenza.
    Virology. 2016;498:226-239.
    PubMed     Text format     Abstract available


    August 2016
  25. PARK SJ, Si YJ, Kim J, Song MS, et al
    Cross-protective efficacies of highly-pathogenic avian influenza H5N1 vaccines against a recent H5N8 virus.
    Virology. 2016;498:36-43.
    PubMed     Text format     Abstract available


    July 2016
  26. ARNDT WD, White SD, Johnson BP, Huynh T, et al
    Monkeypox virus induces the synthesis of less dsRNA than vaccinia virus, and is more resistant to the anti-poxvirus drug, IBT, than vaccinia virus.
    Virology. 2016;497:125-135.
    PubMed     Text format     Abstract available


  27. LIU R, Wang J, Yang Y, Khan I, et al
    Rabies virus lipopeptide conjugated to a TLR7 agonist improves the magnitude and quality of the Th1-biased humoral immune response in mice.
    Virology. 2016;497:102-110.
    PubMed     Text format     Abstract available


  28. JEON JS, Won YH, Kim IK, Ahn JH, et al
    Analysis of single nucleotide polymorphism among Varicella-Zoster Virus and identification of vaccine-specific sites.
    Virology. 2016;496:277-286.
    PubMed     Text format     Abstract available


  29. VELAZQUEZ-SALINAS L, Risatti GR, Holinka LG, O'Donnell V, et al
    Recoding structural glycoprotein E2 in classical swine fever virus (CSFV) produces complete virus attenuation in swine and protects infected animals against disease.
    Virology. 2016;494:178-89.
    PubMed     Text format     Abstract available


    May 2016
  30. GIRIA M, Santos L, Louro J, Rebelo de Andrade H, et al
    Reverse genetics vaccine seeds for influenza: Proof of concept in the source of PB1 as a determinant factor in virus growth and antigen yield.
    Virology. 2016;496:21-27.
    PubMed     Text format     Abstract available


  31. RAI DK, Segundo FD, Schafer E, Burrage TG, et al
    Novel 6xHis tagged foot-and-mouth disease virus vaccine bound to nanolipoprotein adjuvant via metal ions provides antigenic distinction and effective protective immunity.
    Virology. 2016;495:136-147.
    PubMed     Text format     Abstract available


  32. SUN X, Guo N, Li D, Jin M, et al
    Binding specificity of P[8] VP8* proteins of rotavirus vaccine strains with histo-blood group antigens.
    Virology. 2016;495:129-135.
    PubMed     Text format     Abstract available


  33. ALSALEH K, Khou C, Frenkiel MP, Lecollinet S, et al
    The E glycoprotein plays an essential role in the high pathogenicity of European-Mediterranean IS98 strain of West Nile virus.
    Virology. 2016;492:53-65.
    PubMed     Text format     Abstract available


    February 2016
  34. FABURAY B, Gaudreault NN, Liu Q, Davis AS, et al
    Development of a sheep challenge model for Rift Valley fever.
    Virology. 2016;489:128-40.
    PubMed     Text format     Abstract available


    January 2016
  35. DIAZ FM, Knipe DM
    Protection from genital herpes disease, seroconversion and latent infection in a non-lethal murine genital infection model by immunization with an HSV-2 replication-defective mutant virus.
    Virology. 2016;488:61-7.
    PubMed     Text format     Abstract available


    October 2015
  36. HABTE HH, Banerjee S, Shi H, Qin Y, et al
    Immunogenic properties of a trimeric gp41-based immunogen containing an exposed membrane-proximal external region.
    Virology. 2015;486:187-197.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Vaccines is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: